Moderna
MRNA
$140.34
+1.70%
Moderna is a commercial-stage biotechnology company that leverages its proprietary messenger RNA (mRNA) platform to develop a broad pipeline of vaccines and therapeutics across infectious diseases, oncology, cardiovascular disease, and rare genetic disorders. The company rose to global prominence with its COVID-19 vaccine, which validated the platform and established Moderna as a leader in mRNA technology, competing with the likes of Pfizer/BioNTech. Currently, the stock is at the center of intense investor debate following the historic Phase 3 success of its mRNA cancer vaccine with Merck, which has triggered a massive re-rating of the stock, while the company continues to navigate the post-pandemic decline in COVID vaccine sales and heavy R&D spending.…
MRNA
Moderna
$140.34
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating: Hold. Moderna is a speculative buy at current levels, but the risk/reward is balanced. The analyst consensus is 'hold' with an average target of $104.53, implying a -24.3% downside, which suggests the stock is overvalued relative to near-term fundamentals. However, the historic cancer vaccine success provides a strong catalyst that could justify a higher valuation if commercial potential is realized. For investors with a high risk tolerance, a small position could be warranted, but for most, waiting for a better entry point is prudent.
Sign up to view all
MRNA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The recent cancer vaccine breakthrough is a genuine game-changer, but the current valuation already reflects much of the optimism. The company's financials are weak, with negative margins and cash burn, which could limit upside if pipeline monetization is slower than expected. The wide analyst target range underscores uncertainty. I would upgrade to bullish if the stock corrects to below $100, providing a better risk/reward, or if clinical data for other pipeline candidates show strong promise. I would downgrade to bearish if the cancer vaccine faces regulatory setbacks or if the company needs to raise capital at depressed prices.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $106.63 and implied upside of -24.0% versus the current price.
Average Target
$106.63
0 analysts
Implied Upside
-24.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $170
Analyst target range
Moderna is covered by 17 analysts, with a consensus recommendation of 'hold' and a mean rating of 2.74 on a scale where 1 is strong buy and 5 is sell. The average target price is $104.53, which implies a downside of -24.3% from the current price of $137.99, indicating that analysts believe the stock is overvalued at current levels. The target range is wide, from a low of $40.00 to a high of $170.00, reflecting significant uncertainty about the commercial potential of the pipeline, particularly the cancer vaccine. Recent ratings actions have been mixed, with some firms maintaining neutral or underperform ratings, while others have reiterated overweight, suggesting a lack of consensus on the stock's future direction.
Drowning in data?
Find the real signal!
Bulls vs Bears: MRNA Investment Factors
Moderna presents a high-risk, high-reward opportunity. The bull case is anchored by the historic cancer vaccine breakthrough and a diversified pipeline, which have driven a massive re-rating. However, the bear case highlights deep operational losses, a negative gross margin, and an analyst consensus that sees the stock as overvalued. Currently, the bull evidence is stronger in terms of momentum and pipeline potential, but the bear case is compelling on valuation and near-term financials. The central tension is whether the cancer vaccine's commercial potential justifies the current valuation, which is priced for perfection. If clinical and commercial execution falters, the stock could see significant downside toward the analyst low target of $40.
Bullish
- Historic Phase 3 Cancer Vaccine Win: Moderna and Merck announced the first successful Phase 3 trial of an mRNA cancer vaccine, a monumental validation of the platform. This breakthrough has triggered a massive re-rating, with the stock surging over 150% in a single day (from ~$64 to $174) and a 1-year gain of 463.9%.
- Diversified Pipeline Beyond COVID: With 35 mRNA candidates in clinical studies across infectious disease, oncology, cardiovascular, and rare diseases, Moderna is reducing reliance on COVID. The recent FDA win for its flu vaccine adds a near-term commercial opportunity, and the pipeline's optionality is a key driver of long-term value.
- Strong Balance Sheet with Low Debt: Moderna holds a current ratio of 3.29 and a debt-to-equity ratio of only 0.22, indicating ample liquidity and low leverage. This financial flexibility supports continued heavy R&D investment without immediate solvency risk, even with negative cash flow.
- Relative Strength vs. Market: The stock's relative strength over 1 month, 3 months, and 1 year is +147.8%, +190.7%, and +445.4% respectively, vastly outperforming the S&P 500. This momentum reflects strong investor conviction in the pipeline's potential.
Bearish
- Analyst Consensus is Hold with Downside: The average analyst target price is $104.53, implying a -24.3% downside from the current price of $137.99. With a mean rating of 2.74 (hold), analysts see limited upside and potential overvaluation at current levels.
- Deeply Negative Gross Margin in Q1 2026: Gross margin collapsed to -145.5% in Q1 2026, down from +33.3% in Q4 2025, due to lower sales and higher cost of revenue. This indicates severe operational inefficiency and a cash burn that could erode the balance sheet if not reversed.
- Unprofitability and Negative Cash Flow: Moderna reported a net loss of $1.343 billion in Q1 2026, with negative free cash flow of -$1.582 billion TTM. The company remains unprofitable, and continued losses could pressure the stock if the market's patience wears thin.
- Valuation Premium to Industry: The PS ratio of 5.9x matches the industry average, but the EV/Sales of 23.9x is significantly higher, reflecting a premium for pipeline potential. This leaves little room for error; any pipeline setback could trigger a sharp de-rating.
MRNA Technical Analysis
Moderna's stock has undergone a dramatic transformation over the past year, with a 1-year price change of +463.9%, far outpacing the S&P 500's +18.6% gain. The current price of $137.99 sits near the upper end of its 52-week range, at approximately 78% of the high of $176.66 and well above the low of $22.28. This positioning near the highs suggests strong momentum, but also raises the risk of overextension, especially given the stock's beta of 0.899, which indicates slightly lower volatility than the market.
Beta
0.90
0.90x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$22-$177
Price range past year
Annual Return
+482.6%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | +156.0% | +2.7% |
| 3m | +207.5% | +1.0% |
| 6m | +142.8% | +12.0% |
| 1y | +482.6% | +18.9% |
| ytd | +354.8% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Moderna's revenue trajectory has been highly volatile, with Q1 2026 revenue of $389 million representing a 2.6% year-over-year increase, but this follows a period of sharp declines from the COVID peak. The company's gross margin turned deeply negative at -145.5% in Q1 2026, compared to a positive 33.3% in Q4 2025, reflecting the impact of lower sales and higher cost of revenue. The company remains unprofitable, with a net loss of $1.343 billion in Q1 2026, though this loss narrowed from the $1.343 billion loss in Q1 2025, and the EPS of -$3.40 improved from -$2.52 a year ago.
Quarterly Revenue
$389000000.0B
2026-03
Revenue YoY Growth
+263.6%
YoY Comparison
Gross Margin
-145.5%
Latest Quarter
Free Cash Flow
$-1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given Moderna's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 5.9x trailing sales, it reflects the market's high expectations for future growth. The forward PE of -29.8x is not meaningful due to expected losses, but the EV/Sales of 23.9x is significantly higher than the PS ratio, indicating a premium for the company's cash and pipeline. Compared to the biotechnology industry average PS ratio of 5.9x, Moderna trades at a premium, which is justified by its leading mRNA platform and the recent cancer vaccine breakthrough.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Moderna's financials are under severe strain, with Q1 2026 revenue of $389 million barely covering costs, leading to a net loss of $1.343 billion and a gross margin of -145.5%. The company's cash burn is substantial, with TTM free cash flow at -$1.582 billion, though a current ratio of 3.29 and low debt-to-equity of 0.22 provide a cushion. However, if losses persist, the company may need to raise capital or cut R&D, which could impair pipeline progress. Revenue concentration is also a risk, as COVID vaccine sales have declined sharply, and the company is still dependent on a few key products for near-term revenue.
FAQ
The key risks are: 1) Clinical and regulatory setbacks for the cancer vaccine or other pipeline candidates, which could erase the recent gains. 2) Financial risks from continued losses and cash burn, with a net loss of $1.343 billion in Q1 2026 and negative free cash flow of -$1.582 billion TTM. 3) Valuation risk, as the stock trades at a premium to the industry and analyst targets. 4) Competitive risks from other mRNA players like Pfizer/BioNTech. The most severe risk is a pipeline failure, which could send the stock to the 52-week low of $22.28, a -83.8% decline.
The 12-month forecast is uncertain, with a wide range of outcomes. In the bull case (25% probability), the stock could reach $150-$170, driven by cancer vaccine success and other approvals. In the base case (50% probability), the stock is likely to correct to $100-$120, aligning with the analyst average target of $104.53. In the bear case (25% probability), the stock could fall to $40-$60 if pipeline setbacks occur. The most likely scenario is a pullback from current levels, as the recent surge may have overextended the stock.
MRNA is overvalued relative to its current fundamentals. The PS ratio of 5.9x is in line with the industry, but the EV/Sales of 23.9x is significantly higher, reflecting a premium for pipeline potential. The stock is trading at a 32% premium to the analyst average target of $104.53. The market is pricing in successful commercialization of the cancer vaccine and other pipeline assets, which is not yet reflected in earnings. If these expectations are met, the valuation could be justified, but any disappointment could lead to a sharp de-rating.
MRNA is a high-risk, high-reward stock. The recent cancer vaccine success is a major positive, but the stock is trading at $137.99, well above the analyst average target of $104.53, implying a -24.3% downside. The company is unprofitable with a negative gross margin, and the valuation is stretched. For investors with a high risk tolerance and a long-term view, a small position could be justified, but for most, it is not a good buy at current levels. A better entry point would be below $100, where the risk/reward is more balanced.
MRNA is more suitable for long-term investment, given the multi-year timeline for pipeline development and commercialization. The stock is highly volatile, with a beta of 0.899 but a 1-year range from $22.28 to $176.66, making it risky for short-term trading. The company is investing heavily in R&D, and profitability is not expected in the near term. A minimum holding period of 3-5 years is recommended to allow the pipeline to mature. Short-term traders may find opportunities in the volatility, but the risk is high.